221 related articles for article (PubMed ID: 9020489)
1. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.
Hilkens PH; Pronk LC; Verweij J; Vecht CJ; van Putten WL; van den Bent MJ
Br J Cancer; 1997; 75(3):417-22. PubMed ID: 9020489
[TBL] [Abstract][Full Text] [Related]
2. Peripheral neurotoxicity induced by docetaxel.
Hilkens PH; Verweij J; Stoter G; Vecht CJ; van Putten WL; van den Bent MJ
Neurology; 1996 Jan; 46(1):104-8. PubMed ID: 8559354
[TBL] [Abstract][Full Text] [Related]
3. Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel.
Pronk LC; Hilkens PH; van den Bent MJ; van Putten WL; Stoter G; Verweij J
Anticancer Drugs; 1998 Oct; 9(9):759-64. PubMed ID: 9840720
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
Belani CP
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
[TBL] [Abstract][Full Text] [Related]
5. Peripheral neuropathy secondary to docetaxel (Taxotere).
New PZ; Jackson CE; Rinaldi D; Burris H; Barohn RJ
Neurology; 1996 Jan; 46(1):108-11. PubMed ID: 8559355
[TBL] [Abstract][Full Text] [Related]
6. Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer.
Postma TJ; Hoekman K; van Riel JM; Heimans JJ; Vermorken JB
J Neurooncol; 1999; 45(3):241-6. PubMed ID: 10845395
[TBL] [Abstract][Full Text] [Related]
7. Lhermitte's sign following chemotherapy with docetaxel.
van den Bent MJ; Hilkens PH; Sillevis Smitt PA; van Raaij-van den Aarssen VJ; Bontenbal M; Verweij J
Neurology; 1998 Feb; 50(2):563-4. PubMed ID: 9484402
[TBL] [Abstract][Full Text] [Related]
8. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
[TBL] [Abstract][Full Text] [Related]
9. Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer.
Aapro MS
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):46-9. PubMed ID: 9364543
[TBL] [Abstract][Full Text] [Related]
10. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
[TBL] [Abstract][Full Text] [Related]
11. Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel.
Rose PG; Smrekar M
Gynecol Oncol; 2003 Nov; 91(2):423-5. PubMed ID: 14599877
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
Adjei AA; Klein CE; Kastrissios H; Goldberg RM; Alberts SR; Pitot HC; Sloan JA; Reid JM; Hanson LJ; Atherton P; Rubin J; Erlichman C
J Clin Oncol; 2000 Mar; 18(5):1116-23. PubMed ID: 10694565
[TBL] [Abstract][Full Text] [Related]
13. Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity.
van den Bent MJ; van Putten WL; Hilkens PH; de Wit R; van der Burg ME
Eur J Cancer; 2002 Feb; 38(3):387-91. PubMed ID: 11818204
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.
Millward MJ; Zalcberg J; Bishop JF; Webster LK; Zimet A; Rischin D; Toner GC; Laird J; Cosolo W; Urch M; Bruno R; Loret C; James R; Blanc C
J Clin Oncol; 1997 Feb; 15(2):750-8. PubMed ID: 9053501
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
Cascinu S; Graziano F; Barni S; Labianca R; Comella G; Casaretti R; Frontini L; Catalano V; Baldelli AM; Catalano G
Br J Cancer; 2001 Feb; 84(4):470-4. PubMed ID: 11207039
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial.
Blaney SM; Seibel NL; O'Brien M; Reaman GH; Berg SL; Adamson PC; Poplack DG; Krailo MD; Mosher R; Balis FM
J Clin Oncol; 1997 Apr; 15(4):1538-43. PubMed ID: 9193350
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.
de Wit R; Kruit WH; Stoter G; de Boer M; Kerger J; Verweij J
Br J Cancer; 1998 Nov; 78(10):1342-5. PubMed ID: 9823976
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel in combination with fluorouracil for advanced solid tumors.
Burris HA
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):50-2. PubMed ID: 9364544
[TBL] [Abstract][Full Text] [Related]
19. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
